Anlon healthcare Limited has announced a scheduled analyst and investor meeting with S. N. Damani Group for March 21, 2026. The company filed the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, maintaining compliance with regulatory transparency requirements.

Meeting Details and Format

The interaction will be conducted as a physical meeting at the company's Rajkot facility, featuring both a plant visit and management discussion. Chairman and Managing Director Punikumar Rasadia will lead the engagement with the analyst group.

Regulatory Compliance and Information Guidelines

The company has emphasized that all discussions during the meeting will be based exclusively on publicly available information and documents. No unpublished price-sensitive information (UPSI) will be discussed during the interactions, ensuring full compliance with regulatory guidelines.

The meeting schedule remains subject to potential changes, with the company noting that discussions may be cancelled, rescheduled, or postponed due to exigencies from either party. This flexibility ensures both parties can accommodate any unforeseen circumstances while maintaining the planned engagement framework.

Corporate Communication Framework

The disclosure demonstrates Anlon Healthcare's commitment to maintaining transparent investor relations and regulatory compliance. The structured approach to analyst interactions, combined with clear guidelines on information sharing, reflects the company's adherence to corporate governance standards in investor communications.

Neomile Asset Managers Pvt. Ltd. has disclosed a reduction in its stake in Anlon Healthcare Limited through open market transactions conducted by its investment fund. The disclosure was filed in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Transaction Details

Neomile Growth Fund – Series I, managed by Neomile Asset Managers, disposed of 4,07,255 shares in Anlon Healthcare Limited through open market sales. The transactions were executed between March 8-10, 2026, representing 0.76% of the company's total share capital.

Shareholding Changes

The sale resulted in a reduction of Neomile's stake in Anlon Healthcare from 5.16% to 4.40%. The fund's shareholding decreased from 27,45,296 shares to 23,38,041 shares following the disposal.

Company Information

Anlon Healthcare Limited's shares are listed on both the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE). The company's equity share capital remained unchanged at 5,31,51,500 shares throughout the transaction period. Neomile Growth Fund – Series I is not part of the promoter or promoter group of Anlon Healthcare.

Regulatory Compliance

The disclosure was signed by CA Rashesh Shah, Director of Neomile Asset Managers Pvt. Ltd., and filed with both stock exchanges and the target company on March 11, 2026. The fund holds PAN number AAETN3197R and operates from Mumbai. The transaction involved only equity shares carrying voting rights, with no encumbrances, warrants, or convertible securities involved in the disposal.